Shares of UroGen Pharma (URGN) have resumed trading and are down $3.96, or 52%, to $3.59 after the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration voted 4 to 5 that the benefit/risk of UGN-102 for intravesical solution was favorable for the treatment of recurrent LG-IR-NMIBC. “While we are disappointed by today’s outcome, we continue to believe our clinical data support UGN-102 for the treatment of recurrent LG-IR-NMIBC, a disease with no FDA-approved therapies,” said CEO Liz Barrett.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN: